- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
Medicinal packaging doesn’t have to be harsh and strident. That’s the concept behind the biosimilar packaging for which Samsung Bioepis continues to earn international awards. Most recently, Samsung Bioepis has garnered International Forum (iF) Design Award 2021 honors for packaging.
Soft shapes and soothing mono-colors characterize the package designs for Samsung Bioepis’ drug products, which include biosimilars. The company, based in Incheon, Republic of Korea, has called its package design concept “Passion for Health—Pure Joy in Life.”
“Taking medication can be a constant reminder of the medical condition, and we wanted to remind patients of ‘pure joy’ in life when they look at our product packaging and design,” Jaywoo Kim, senior vice president and manufacturing division leader at Samsung Bioepis, said in a statement.
The company won in 2 categories: Packaging—Medicine/Pharmaceutics and Communication—Corporate Identity/Branding.
In 2020, the company won package design awards in the Red Dot competition.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
